利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.019 秒)

    Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
    2.
    发明授权
    Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase 失效
    纤维蛋白（ogen）纤维蛋白溶解基质金属蛋白酶降解

    公开(公告)号：US5830468A

    公开(公告)日：1998-11-03

    申请号：US446887

    申请日：1995-05-17

    申请人： Alessandra Bini

    发明人： Alessandra Bini

    IPC分类号： A61L33/00 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61K38/55 ,  A61K48/00 ,  A61P7/02 ,  A61P9/10 ,  C07K1/12 ,  A61M5/00 ,  B65D51/24 ,  C12N9/50

    CPC分类号： A61K38/4886

    摘要： The invention provides a method of causing the degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic metalloproteinase, such as MMP-3. The method of the invention may be performed in vitro to provide diagnostic information characterizing fibrin(ogen) and the fibrinolytic physiology. The method may also be performed in vivo as a method of thrombolytic therapy in which a fibrinolytic metalloproteinase is administered to a subject to degrade thrombus in situ. The invention further provides compositions containing a fibrinolytic metalloproteinase for the performance of fibrinolytic or thrombolytic procedures. Also provided are kits which include a fibrinolytic metalloproteinase for performing fibrinolytic or thrombolytic procedures.

    摘要翻译： 本发明提供了通过纤维蛋白溶解性金属蛋白酶（例如MMP-3）引起纤维蛋白（原子）（即纤维蛋白，纤维蛋白原和相关物质）降解的方法。 本发明的方法可以在体外进行以提供表征纤维蛋白（ogen）和纤维蛋白溶解生理学的诊断信息。 该方法还可以在体内作为血栓溶解治疗的方法进行，其中向受试者施用纤维蛋白溶解性金属蛋白酶以原位降解血栓。 本发明还提供含有纤维蛋白溶解性金属蛋白酶用于纤维蛋白溶解或血栓溶解过程的组合物。 还提供了包括用于进行纤维蛋白溶解或血栓溶解过程的纤维蛋白溶解性金属蛋白酶的试剂盒。

    Method of preparing red blood cell and platelet products
    4.
    发明授权
    Method of preparing red blood cell and platelet products 有权
    制备红细胞和血小板产品的方法

    公开(公告)号：US09394518B2

    公开(公告)日：2016-07-19

    申请号：US14598938

    申请日：2015-01-16

    申请人： New York Blood Center, Inc.

    发明人： Beth H. Shaz ,  Christopher D. Hillyer

    IPC分类号： A61K35/14 ,  C12N5/078 ,  A61M1/02 ,  A01N1/02

    CPC分类号： C12N5/0641 ,  A01N1/02 ,  A01N1/021 ,  A01N1/0226 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K35/19 ,  A61M1/0272 ,  A61M1/342 ,  A61M1/3496 ,  A61M2202/0429 ,  A61M2202/20 ,  C12N5/0644

    摘要： This disclosure provides methods for preparing both a red blood cell (RBC)-containing product and a platelet-containing product from a plurality of blood units. The method comprises leukoreducing a plurality of blood units, separating RBCs, platelets, and plasma from the units to form leukoreduced blood components, pooling the leukoreduced RBC components; pooling the leukoreduced platelet components, treating the pooled components to inactivate one or more pathogens, adding a storage solution to components, dividing the pooled leukoreduced RBCs into a plurality of RBC-containing product units, each having a uniform number of RBCs, and dividing the pooled leukoreduced platelets into a plurality of platelet-containing product units, each having a uniform number of platelets.

    摘要翻译： 本公开提供了制备来自多个血液单元的含红细胞（RBC）的产物和含血小板的产品的方法。 该方法包括白细胞减少多个血液单元，从该单元分离RBC，血小板和血浆以形成白细胞减少的血液成分，汇集白细胞减少的RBC组分; 汇集白细胞减少的血小板成分，处理汇集的组分以灭活一种或多种病原体，向组分中加入储存溶液，将合并的白细胞减少的红细胞分成多个含有RBC的产物单元，每个RBC含有均一数目的RBC， 汇集的白细胞减少的血小板分成多个含血小板的产品单元，每个产品单元具有均匀数量的血小板。

    Method for purifying viral nucleic acids
    5.
    发明授权
    Method for purifying viral nucleic acids 失效
    病毒核酸纯化方法

    公开(公告)号：US5958677A

    公开(公告)日：1999-09-28

    申请号：US900907

    申请日：1997-07-28

    申请人： Dong-Hun Lee ,  Alfred M. Prince

    发明人： Dong-Hun Lee ,  Alfred M. Prince

    IPC分类号： C12P19/34 ,  C12Q20060101 ,  C12Q1/68 ,  C12Q1/70

    CPC分类号： C12Q1/6806 ,  B01D61/14 ,  B01D71/32 ,  C12N2730/10151 ,  C12N2740/16051 ,  C12N2770/24251 ,  C12N2770/32451 ,  C12Q1/701

    摘要： The invention relates to a method for purification of viral RNA from a biological sample. The method involves lysing the virus envelope to liberate the RNA and passing the lysate through a porous hydrophilic PVDF filter to capture the viral RNA. The filter with bound RNA is then washed to remove proteins, lipids and other contaminants. The RNA is released from the filter using a low ionic strength ribonuclease (RNase) free solution to form a solution containing purified viral RNA. From this solution the RNA is recovered. The invention is also compatible with purification of nucleic acids from other types of samples.

    摘要翻译： 本发明涉及从生物样品中纯化病毒RNA的方法。 该方法包括裂解病毒包膜以释放RNA并使裂解物通过多孔亲水性PVDF过滤器捕获病毒RNA。 然后洗涤具有结合RNA的过滤器以除去蛋白质，脂质和其它污染物。 使用低离子强度核糖核酸酶（RNase）的溶液从RNA滤出RNA，形成含有纯化病毒RNA的溶液。 从该溶液中回收RNA。 本发明还与来自其他类型样品的核酸的纯化相容。

    Diagnostic method and kit for determining Rh blood group genotype
    6.
    发明授权
    Diagnostic method and kit for determining Rh blood group genotype 失效
    用于确定Rh血型基因型的诊断方法和试剂盒

    公开(公告)号：US5723293A

    公开(公告)日：1998-03-03

    申请号：US553888

    申请日：1995-11-06

    申请人： Cheng-Han Huang

    发明人： Cheng-Han Huang

    IPC分类号： C12N15/09 ,  C12Q1/68 ,  C07H21/04 ,  C12N15/00 ,  G01N33/555

    CPC分类号： C12Q1/6881 ,  C12Q1/683 ,  C12Q2600/156 ,  C12Q2600/172 ,  Y10S435/81

    摘要： The invention provides a diagnostic method of determining Rh genotypes by the identification of the molecular basis of Rh polymorphisms. Specifically, the invention provides a method for directly determining Dd and associated CcEe genotypes with great accuracy, overcoming problems associated with traditional serologic typing methods and leading to a direct discrimination of D/D, D/d, and d/d genetic status. The diagnostic method allows genotyping of fetuses to assess the risk of hemolytic diseases caused by Rh alloimmunization and genetic counseling and/or testing of couples to predict the outcome of pregnancies in relation to Rh incompatibilities. The method of the invention preferably employs amplification of Rh nucleic acid sequences, and employs differential cleavage of RhD-, RhCc- and/or RhEe-specific nucleic acid sequences by a restriction enzyme. Furthermore, diagnostic kits for the determination of Rh genotypes are provided.

    摘要翻译： 本发明提供了通过鉴定Rh多态性的分子基础来确定Rh基因型的诊断方法。 具体地说，本发明提供了一种以高精度直接测定Dd和相关CcEe基因型的方法，克服了与传统血清学分型方法相关的问题，导致直接鉴别D / D，D / d和d / d基因状态。 诊断方法允许胎儿进行基因分型，以评估Rh同种异体免疫和遗传咨询和/或夫妇检测引起的溶血性疾病的风险，以预测与Rh不相容性相关的妊娠结局。 本发明的方法优选使用Rh核酸序列的扩增，并采用限制性酶对RhD-，RhCc-和/或RhEe-特异性核酸序列进行差异切割。 此外，提供了用于确定Rh基因型的诊断试剂盒。

    Monospecific antibody reactive with Fibrinogen and fibrinopeptide B
    7.
    发明授权
    Monospecific antibody reactive with Fibrinogen and fibrinopeptide B 失效
    与纤维蛋白原和纤维蛋白肽B反应的单特异性抗体

    公开(公告)号：US5876947A

    公开(公告)日：1999-03-02

    申请号：US900660

    申请日：1997-07-25

    申请人： Bohdan J. Kudryk ,  Colvin M. Redman ,  Jian-Zhong Zhang

    发明人： Bohdan J. Kudryk ,  Colvin M. Redman ,  Jian-Zhong Zhang

    IPC分类号： C07K16/18 ,  C12P21/08 ,  G01N33/86 ,  G01N33/53 ,  C07K16/36 ,  G01N33/536 ,  G01N33/543

    CPC分类号： C07K16/18 ,  G01N33/86 ,  Y10S435/972 ,  Y10S435/975

    摘要： The invention provides monospecific antibodies that are specifically reactive with fibrinopeptide B (FPB) and with fibrinogen and fragments thereof containing the amino acid sequence defined by SEQ ID NO:1. The invention also provides anti-FPB probes, including monospecific anti-FPB antibodies that have been detectably labeled. In addition, the invention provides methods of using the monospecific antibodies for detection of fibrinopeptide B, as well as reagents and kits for performing the methods. For example, the invention provides a method for detecting fibrinopeptide B with specificity in biological samples such as blood samples, by using the antibody to immunometrically bind to the fibrinopeptide B. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis. The invention further provides continuous cell lines (hybridomas) that produce monospecific anti-FPB antibodies.

    摘要翻译： 本发明提供了与纤维蛋白肽B（FPB）特异性反应的单特异性抗体以及含有由SEQ ID NO：1定义的氨基酸序列的纤维蛋白原及其片段。 本发明还提供抗FPB探针，包括可检测标记的单特异性抗FPB抗体。 此外，本发明提供了使用单特异性抗体检测纤维蛋白肽B的方法，以及用于进行该方法的试剂和试剂盒。 例如，本发明提供了通过使用免疫结合纤维蛋白肽B的抗体来检测生物样品例如血液样品中特异性的纤维蛋白肽B的方法。用于确定与动脉粥样化形成和/或血栓形成相关的信息的诊断方法。 本发明还提供产生单特异性抗FPB抗体的连续细胞系（杂交瘤）。

    Monospecific antibodies against a subunit of fibrinogen
    8.
    发明授权
    Monospecific antibodies against a subunit of fibrinogen 失效
    针对纤维蛋白原亚单位的单特异性抗体

    公开(公告)号：US5817768A

    公开(公告)日：1998-10-06

    申请号：US479755

    申请日：1995-06-07

    申请人： Gerd Grieninger ,  Yiping Fu ,  Yan Cao ,  Mohamad Zaher Ahadi ,  Bohdan J. Kudryk

    发明人： Gerd Grieninger ,  Yiping Fu ,  Yan Cao ,  Mohamad Zaher Ahadi ,  Bohdan J. Kudryk

    IPC分类号： C12N15/02 ,  C07K16/18 ,  C07K16/36 ,  C12N5/10 ,  C12P21/08 ,  G01N33/50 ,  G01N33/53 ,  G01N33/577 ,  C07K16/00 ,  C07K17/00

    CPC分类号： C07K16/18 ,  G01N2333/75

    摘要： The invention provides nonspecific antibodies which are specifically reactive with the .alpha..sub.E subunit of fibrinogen or a fragment thereof, but not with other portions of the fibrinogen molecule. The invention also provides anti-.alpha..sub.E probes, including nonspecific anti-.alpha..sub.E antibodies which have been detectably labeled. In addition, the invention provides methods of using the nonspecific antibodies for detection of the .alpha..sub.E subunit and fragments thereof, as well as reagents and kits for performing the methods. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis, as well as for determining information associated with pregnancy status or outcome. The invention further provides continuous cell lines which produce monospecific anti-.alpha..sub.E antibodies.

    摘要翻译： 本发明提供了非特异性抗体，其与纤维蛋白原的αE亚单位或其片段特异性反应，但不与纤维蛋白原分子的其它部分反应。 本发明还提供了抗αE探针，包括可检测标记的非特异性抗αE抗体。 此外，本发明提供使用非特异性抗体检测αE亚基及其片段的方法，以及用于进行该方法的试剂和试剂盒。 用于确定与动脉粥样化形成和/或血栓形成相关的信息的诊断方法，以及用于确定与怀孕状态或结果相关的信息。 本发明还提供产生单特异性抗αE抗体的连续细胞系。

    Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fibrin I or human fibrin II
    9.
    发明授权
    Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fibrin I or human fibrin II 失效
    对来自人纤维蛋白原，人纤维蛋白I或人纤维蛋白II的体内片段特异性的单克隆抗体

    公开(公告)号：US4851334A

    公开(公告)日：1989-07-25

    申请号：US84002

    申请日：1987-08-10

    申请人： Bohdan J. Kudryk ,  Michael E. Wiebe

    发明人： Bohdan J. Kudryk ,  Michael E. Wiebe

    IPC分类号： A61K35/14 ,  A61K38/00 ,  A61M1/36 ,  C07K16/18 ,  G01N33/86

    CPC分类号： G01N33/86 ,  A61M1/3687 ,  C07K14/75 ,  C07K16/18 ,  G01N2333/75

    摘要： Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrinogen or fibrin I containing amino acid residues 1-42. The hybridoma is formed by fusing an animal myeloma cell, e.g., mouse myeloma cell, with a splenocyte from an animal, e.g., a mouse, immunized with an NH.sub.2 -terminal of human fibrinogen or fibrin I. Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrin II containing amino acid residues 15-42. The hybridoma is formed by fusing an animal, e.g., mouse myeloma cell with a splenocyte from an animal, e.g., mouse, immunized with a NH.sub.2 -terminal of human fibrin II. Diagnostic and therapeutic uses of the monoclonal antibodies are also disclosed.

    摘要翻译： 用于在人纤维蛋白原的Bβ链或含有氨基酸残基1-42的纤维蛋白I的肽片段上发现的抗原单克隆抗体的杂交瘤。 通过将动物骨髓瘤细胞例如小鼠骨髓瘤细胞与来自动物的脾细胞（例如，用人纤维蛋白原或纤维蛋白I的NH 2端免疫的小鼠）融合来形成杂交瘤。用于产生单克隆抗体的杂交瘤 在含有氨基酸残基15-42的人纤维蛋白II的Bβ链的肽片段上发现的抗原。 通过将动物（例如小鼠骨髓瘤细胞）与来自人纤维蛋白II的NH 2 - 末端免疫的动物例如小鼠的脾细胞融合来形成杂交瘤。 还公开了单克隆抗体的诊断和治疗用途。